ALFA FinderBSE filing, NSE: JAGSNPHARM. Summary written from the filing by ALFA Finder's alert engine.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹213.21
- Market cap
- ₹1,406 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 30.9×Sector 43.0×
- Promoter holding
- 68.81%-0.24% QoQ
- FII holding
- 2.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹964 Mn (+29%, Aequitas consolidated); standalone revenue ₹814 Mn (+9.3%), EBITDA margin 22.7%, PAT ₹126 Mn flat. H1 standalone PAT +10.3%.
Jagsonpal Pharmaceuticals Results Update
Jagsonpal reported Q2 FY27 consolidated revenue up 29% to ₹964 Mn, with standalone revenue up 9.3%. Standalone H1 PAT grew 10.3% and cash stood at ₹1,347 Mn.
Jagsonpal Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.6 Cr, Up 0.0% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+9.3% YoY) and net profit of ₹12.6 Cr (+0.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.6 Cr · +0.0% YoY
Jagsonpal Pharmaceuticals Board Meeting Date
Jagsonpal Pharmaceuticals Ltd will hold a Board Meeting on October 28, 2026, to consider and approve the company's unaudited financial results for the quarter ended September 30, 2026.
Jagsonpal Pharmaceuticals Other Announcement
Jagsonpal Pharmaceuticals Ltd filed its quarterly shareholding pattern statement in compliance with SEBI Regulation 31(1)(b).
Jagsonpal Pharmaceuticals Acquisition
Jagsonpal Pharmaceuticals has completed the acquisition of the Wellness Portfolio from Group Pharmaceuticals Limited, following the fulfilment of all conditions precedent in the agreement.
- From
- Group Pharmaceuticals Limited
Other business update announcements
All →Italian Edibles Business Update
Italian Edibles revised its project timeline again, pushing commercial production from January 2027 to April 2027. Construction delays stem from steel prices, supply chain disruption, weather and labour shortages.
- Execution
- Commercial production revised to April 2027 from January 2027
Bajaj Finserv Business Update
Bajaj Finserv disclosed October 2026 monthly premium and new business data for its unlisted insurance subsidiaries. The figures are provisional.
Bajaj Finance Business Update
Bajaj Finance submitted its Half Yearly Report for FY2026-27 covering the six months to 30 September 2026. The report shows 28% consolidated PAT growth to ₹12,447 crore and a planned ₹17,500 crore capital raise.
Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Religare Enterprises Business Update
Religare Finvest, a material subsidiary, resumed lending after RBI lifted its Corrective Action Plan. It disbursed its first Loan Against Property on 6 November 2026.
Purple Wave Infocom Business Update
Purple Wave signed a 5-year data integration agreement with BPCL for its Hygiair devices. The Rs 10 crore figure is indicative, not firm order value.
- Execution
- 5 years